RomiCar trial

Chief investigator - Dr Graham Collins, Oxford University Hospitals NHS Trust
Cancer type - Lymphoma, Burkitt lymphoma
A phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Award start date: 01 Aug 2015
Recruitment start date: 31 Jul 2015
Award duration: 4.5 years (54 months)

Peripheral T-cell lymphoma (PTCL) is a particularly aggressive and difficult to treat non-Hodgkin lymphoma, which has relatively poor outcomes.

People with PTCL are usually given chemotherapy, but sometimes it continues to grow, or comes back after the treatment has finished.

This trial is looking at two drugs called romidepsin and carfilzomib.

Romidepsin inhibits proteins (enzymes) called histone deacetylases - cells need these enzymes to grow and divide. Drugs that block these enzymes are called histone deacetylase inhibitors, or HDAC inhibitors. Carfilzomib is a type of biological therapy called a proteasome inhibitor that also blocks cancer growth by stoppings signals that cancer cells use to divide and grow.

Researchers want to know if combining romidepsin and carfilzomib could help people with PTCL that has come back, or standard treatment has stopped working for them.

The aims of the trial are to:

  • Find the best dose of romidepsin and carfilzomib
  • Find out  if the combination of romidepsin and carfilzomib can help people with PTCL
  • Learn more about the side effects

You may be eligible to join this trial if:

  • You have PTCL that has come back or treatment has stopped working
  • You are at least 16 years old